Fractyl Health, Bariendo sign non-binding LOI, to offer Revita nationwide

Fractyl Health (GUTS) and Bariendo announced the signing of a non-binding Letter of Intent, LOI, to explore a future collaboration centered on Fractyl’s investigational Revita procedure as a durable off-ramp for weight maintenance following GLP-1 drug discontinuation. This agreement comes as Fractyl prepares for three key data readouts from its ongoing pivotal study of Revita: REVEAL-1 Cohort open-label data expected in June 2025; REMAIN-1 Midpoint Cohort data expected in the third quarter of 2025; and 6-month primary endpoint data from the REMAIN-1 Pivotal Cohort expected in the second half of 2026. Together, these clinical milestones are designed to demonstrate Revita’s potential to help maintain weight loss after GLP-1 discontinuation and inform its possible role in supporting durable metabolic outcomes. Bariendo brings to the partnership a scalable, physician-driven platform designed to deliver a holistic approach to obesity, including metabolic endoscopic solutions at the nation’s largest network of high-volume hospital and ambulatory endoscopy centers across the United States